Development of DNA Vaccine Candidate against SARS-CoV-2.
Viruses
; 14(5)2022 05 15.
Article
in English
| MEDLINE | ID: covidwho-1855823
ABSTRACT
Despite the existence of various types of vaccines and the involvement of the world's leading pharmaceutical companies, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains the most challenging health threat in this century. Along with the increased transmissibility, new strains continue to emerge leading to the need for more vaccines that would elicit protectiveness and safety against the new strains of the virus. Nucleic acid vaccines seem to be the most effective approach in case of a sudden outbreak of infection or the emergence of a new strain as it requires less time than any conventional vaccine development. Hence, in the current study, a DNA vaccine encoding the trimeric prefusion-stabilized ectodomain (S1+S2) of SARS-CoV-2 S-protein was designed by introducing six additional prolines mutation, termed HexaPro. The three-dose regimen of designed DNA vaccine immunization in mice demonstrated the generation of protective antibodies.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Viral Vaccines
/
Vaccines, DNA
/
COVID-19
Type of study:
Observational study
Topics:
Vaccines
Limits:
Animals
Language:
English
Year:
2022
Document Type:
Article
Affiliation country:
V14051049
Similar
MEDLINE
...
LILACS
LIS